Ann M. Gregus

Ann M. Gregus

Auto-generated profile, based on publicly available information

Ann M. Gregus

School of Neuroscience, Virginia Polytechnic and State University, 970 Washington Street SW, Blacksburg, VA, 24061, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2023 in Neurobiology of Pain
Verified
Journal Article
Open access
ICIrene Chen
Irene Chen
LMLaura B. Murdaugh
Laura B. Murdaugh
CMCristina Miliano
Cristina Miliano
YDYuyang Dong
Yuyang Dong
AGAnn M. Gregus
Ann M. Gregus
MBMatthew W. Buczynski
Matthew W. Buczynski
N-acyl-ethanolamine (NAEs) serve as key endogenous lipid mediators as revealed by manipulation of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for metabolizing NAEs. Preclinical studies focused on FAAH or NAE receptors indicate an important role for NAE signaling in nociception and affective behaviors. However, there is limited information on the role of NAE biosynthesis in these same behavioral paradigms. Biosynthesis of NAEs has been attributed largely to the enzyme N-acylphosphatidylethanolamine Phospholipase D (NAPE-PLD), one of three pathways capable of producing these bioactive lipids in the brain. In this report, we demonstrate that Nape-pld knockout (KO) mice displayed reduced sucrose preference and consumption, but other baseline anxiety-like or depression-like behaviors were unaltered. Additionally, we observed sex-dependent responses in thermal nociception and other baseline measures in wildtype (WT) mice that were absent in Nape-pld KO mice. In the Complete Freund's Adjuvant (CFA) model of inflammatory arthritis, WT mice exhibited sex-dependent changes in paw edema that were lost in Nape-pld KO mice. However, there was no effect of Nape-pld deletion on arthritic pain-like behaviors (grip force deficit and tactile allodynia) in either sex, indicating that while NAPE-PLD may alter local inflammation, it does not contribute to pain-like behaviors associated with inflammatory arthritis. Collectively, these findings indicate that chronic and systemic NAPE-PLD inactivation will likely be well-tolerated, warranting further pharmacological evaluation of this target in other disease indications.

7 March 2022 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
ALAmanda Laque
Amanda Laque
GWGrant E. Wagner
Grant E. Wagner
AMAlessandra Matzeu
Alessandra Matzeu
GNGenna L. De Ness
Genna L. De Ness
TKTony M. Kerr
Tony M. Kerr
NSNobuyoshi Suto
Nobuyoshi Suto

2 September 2025 in Alcohol
Verified
Journal Article
Closed access
YDYuyang Dong
Yuyang Dong
MBMatthew W. Buczynski
Matthew W. Buczynski
AGAnn M. Gregus
Ann M. Gregus

11 May 2025 in Neuropharmacology
Verified
Journal Article
Closed access
CMCristina Miliano
Cristina Miliano
YDYuyang Dong
Yuyang Dong
MPMcKenzie Proffit
McKenzie Proffit
NCNatalia Corvalan Cabanas
Natalia Corvalan Cabanas
LNLuis A. Natividad
Luis A. Natividad
AGAnn M. Gregus
Ann M. Gregus

10 July 2025 in Pain
Verified
Journal Article
Closed access
CMCristina Miliano
Cristina Miliano
ICIrene Chen
Irene Chen
BBBrieann Brown
Brieann Brown
LMLaura B. Murdaugh
Laura B. Murdaugh
YDYuyang Dong
Yuyang Dong
AGAnn M. Gregus
Ann M. Gregus
Chronic nociplastic pain syndromes are characterized by sensitization of peripheral and central nervous systems and exhibit increased incidence in women. However, nonsteroidal anti-inflammatory drugs are ineffective in mitigating nociplastic pain, and current prescription treatments, such as opioids, anticonvulsants, and antidepressants, provide limited therapeutic benefit for these indications. In the current work, we extended previous studies in rats of central Toll-like receptor 4–dependent pain hypersensitivity to male and female C57BL/6N mice, uncovering an unexpected hyperalgesic phenotype in female mice following intrathecal (IT) lipopolysaccharide (LPS). In contrast to previous reports in female C57BL/6J mice, female C57BL/6N mice displayed tactile and cold allodynia, grip force deficits, and a modest increase in locomotor activity in response to IT LPS. Congruent with our previous observations in male rats, LPS released spinal 12/15-lipoxygenase (12/15-LOX) metabolites (12/15-LMs) in female C57BL/6N mice. Likewise, 12/15-LOX enzymes are basally expressed in multiple tissues and cell types relevant to nociceptive transmission. Systemic inhibition of 12/15-LOX in female C57BL/6N mice with selective inhibitors ML355 (targeting 12-LOX-p) or ML351 (targeting 15-LOX-1) completely reversed allodynia and grip force deficits. 12/15-LMs also produce tactile allodynia when administered spinally (IT) or peripherally (paw intraplantar) at a subthreshold dose in a hyperalgesic priming model, similar to others' observations with a subthreshold dose of the cyclooxygenase metabolite prostaglandin E 2 . Collectively, these data suggest that 12/15-LOX enzymes contribute to peripheral and central pain hypersensitivity in rodents, with potential translatability as druggable targets across sexes and species using multiple reflexive and functional outcome measures.